Lybalvi Tablet, Film Coated
Product Images NDC 65757-651

12 FDA label images from Alkermes, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Lybalvi (NDC 65757-651). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alkermes, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Olanzapine Chemical Structure (Lyb01 0020 01)

Olanzapine Chemical Structure (Lyb01 0020 01)
Chemical structure diagram of the active ingredients olanzapine and samidorphan l-malate, showing the molecular arrangement of atoms and chemical bonds.*
FDA Label Image

Samidorphan L-malate Chemical Structure (Lyb01 0020 02)

Samidorphan L-malate Chemical Structure (Lyb01 0020 02)
Chemical structure diagram of the active ingredient olanzapine and samidorphan l-malate, showing the molecular configuration with labeled rings, functional groups, and the l-malate moiety.*
FDA Label Image

Figure 1 (Lyb01 0020 03)

Figure 1 (Lyb01 0020 03)
A forest plot chart showing fold change and 90% confidence intervals for olanzapine and samidorphan in individuals with moderate hepatic impairment and severe renal impairment. The horizontal axis represents the change relative to healthy controls, with points indicating Cmax and AUC∞ values for both drugs under each impairment condition.*
FDA Label Image

Figure 2 (Lyb01 0020 04)

Figure 2 (Lyb01 0020 04)
A chart showing the geometric mean ratio and 90% confidence intervals for olanzapine and samidorphan pharmacokinetic parameters (Cmax and AUC∞) under the effect of the strong CYP3A4 inducer rifampin. The x-axis represents change relative to reference without rifampin, ranging from 0.00 to 1.50.*
FDA Label Image

Figure 3 (Lyb01 0020 05)

Figure 3 (Lyb01 0020 05)
A plot titled 'Geometric Mean Ratio and 90% Confidence Intervals' depicting the relative change in Cmax and AUC12h for Lithium and Valproate compared to a reference without LYBALVI. The x-axis represents the change relative to reference, ranging from 0.00 to 1.50, with plotted points and error bars for both drugs' parameters around the value 1.00.*
FDA Label Image

Figure 4 (Lyb01 0020 06)

Figure 4 (Lyb01 0020 06)
A line graph depicting change in PANSS Total Score over 4 weeks for three groups: placebo, olanzapine, and LYBALVI. The x-axis represents weeks from 0 to 4, while the y-axis shows change in score from 0 to -30. Data points include error bars, and a table below the graph shows subject counts per group at each week.*
FDA Label Image

Figure 5 (Lyb01 0020 07)

Figure 5 (Lyb01 0020 07)
A line graph depicting the percentage change in body weight over 24 weeks for two groups: olanzapine (open circles) and LYBALVI (solid circles). The x-axis shows the time in weeks, and the y-axis shows the percent change in body weight with error bars indicating variability. The graph shows that weight change increases over time for both groups, with olanzapine showing greater weight gain compared to LYBALVI.*
FDA Label Image

Alkermes Logo (Lyb01 0020 08)

FDA Label Image

Principal Display Panel (5 mg/10 mg 30 Tablets Carton Label)

Principal Display Panel (5 mg/10 mg 30 Tablets Carton Label)
Packaging label for LYBALVI tablets containing olanzapine and samidorphan. The strength shown is 5 mg/10 mg, with a count of 30 film-coated tablets per package. The label includes the NDC 65757-651-42, manufacturer Alkermes, Inc., and features dosage and storage information, inactive ingredients, and a barcode. The design includes a brown and blue curved stripe.*
FDA Label Image

Principal Display Panel (10 mg/10 mg 30 Tablets Carton Label)

Principal Display Panel (10 mg/10 mg 30 Tablets Carton Label)
Packaging label for Lybalvi 10 mg/10 mg tablets, a film-coated tablet containing olanzapine and samidorphan l-malate. The label indicates a package of 30 tablets, distributed by Alkermes, Inc. The design includes dosage information, inactive ingredients, storage instructions, and a barcode with NDC 65757-652-42.*
FDA Label Image

Principal Display Panel (15 mg/10 mg 30 Tablets Carton Label)

Principal Display Panel (15 mg/10 mg 30 Tablets Carton Label)
Packaging label for LYBALVI tablets containing olanzapine and samidorphan, 15 mg/10 mg strength. The film-coated tablet box is for 30 tablets and labeled Rx only. Manufactured and distributed by Alkermes, Inc., the label includes storage instructions, inactive ingredients, and patient support contact information.*
FDA Label Image

Principal Display Panel (20 mg/10 mg 30 Tablets Carton Label)

Principal Display Panel (20 mg/10 mg 30 Tablets Carton Label)
Carton label for LYBALVI tablets containing olanzapine and samidorphan with a strength of 20 mg / 10 mg, film-coated tablets. The label shows a package size of 30 tablets, with red, blue, and copper gradient design elements. Distributed by Alkermes, Inc., includes storage instructions and inactive ingredients list, and a barcode with NDC 65757-654-42.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.